Pfizer is reportedly seeking approval for a 4th dose of COVID-19 vaccines for seniors

Pfizer COVID-19 vaccine for seniors
(Image credit: FREDERIC J. BROWN/AFP via Getty Images)

Pfizer is expected to seek authorization for a fourth dose in its COVID-19 vaccine regimen for seniors, The Associated Press reported Tuesday.

The additional booster shot would go to Americans 65 and older, in an effort to provide additional protection to age groups that are more vulnerable to serious illness by the coronavirus.

Pfizer has not yet submitted its request to the Food and Drug Administration and the Centers for Disease Control, but CEO Albert Bourla said earlier this week he believes a fourth dose is necessary. "The protection that you are getting from the third [dose], it is good enough, actually quite good for hospitalizations and deaths," he told CBS's Face the Nation. "It's not that good against infections, but doesn't last very long. But we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

Pfizer has rolled out COVID-19 vaccines and boosters with varying regimens for specific age groups. Most recently, it postponed its request for approval for a shot for kids under age 5, saying it wants to compare data between a two-dose and three-dose regimen.

To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us